Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
-
New imaging agent shows promise for kidney cancer detection
Diagnosis CompletedThis study tested a new radioactive imaging agent called 68Ga-OncoCAIX in 20 people with clear cell renal cell carcinoma, a type of kidney cancer. The goal was to see if it is safe and how it spreads in the body to help detect tumors. Participants received a single dose, and rese…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Diagnosis
Last updated May 26, 2026 05:02 UTC
-
New scan agent shows promise for spotting prostate cancer
Diagnosis CompletedThis study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and to measure how much radiation the body receives. The agent helps doctors see where the cancer is located using a special scan.
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Diagnosis
Last updated May 22, 2026 13:55 UTC